The company’s sales revenue increased to RON45.8 million, against RON36.8 million in January-March 2014.
In the first quarter of 2014, the company reported net profit of RON9.9 million.
Biofarm’s operating profit rose 40.2% to RON16.4 million in the first three months, from RON11.7 million in the year-ago period.
Biofarm, whose shares are listed on the Bucharest stock exchange, is controlled by three of Romania’s five regional investment funds, known as SIFs. SIF Muntenia (SIF4.RO) owns 45.9% of the drugmaker’s shares, SIF Banat-Crisana (SIF1.RO) has a 19.5% interest, while SIF Moldova (SIF2.RO) holds 12.2% in the company.